Phase 2, multi-center, randomized, double-blind, placebo-controlled, 3 arm, 12-month study to evaluate the effects of GPI 1485 on erectile function in patients undergoing bilateral nerve-sparing radical retropubic prostatectomy for prostatic carcinoma

Trial Profile

Phase 2, multi-center, randomized, double-blind, placebo-controlled, 3 arm, 12-month study to evaluate the effects of GPI 1485 on erectile function in patients undergoing bilateral nerve-sparing radical retropubic prostatectomy for prostatic carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2009

At a glance

  • Drugs GM 1485 (Primary)
  • Indications Erectile dysfunction
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 05 Nov 2008 Sponsor and affiliate changed from MGI Pharma to Eisai Medical Research, based on information from ClinicalTrials.gov.
    • 21 Apr 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
    • 18 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top